Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. Newby, D., Prieto-Alhambra, D., Duarte-Salles, T., Ansell, D., Pedersen, L., van der Lei, J., Mosseveld, M., Rijnbeek, P., James, G., Alexander, M., Egger, P., Podhorna, J., Stewart, R., Perera, G., Avillach, P., Grosdidier, S., Lovestone, S., & Nevado-Holgado, A. J. Alzheimers Res Ther, 12(1):38, 2020. 1758-9193 Newby, Danielle Prieto-Alhambra, Daniel Duarte-Salles, Talita Ansell, David Pedersen, Lars van der Lei, Johan Mosseveld, Mees Rijnbeek, Peter James, Glen Alexander, Myriam Egger, Peter Podhorna, Jana Stewart, Robert Perera, Gayan Avillach, Paul Grosdidier, Solène Lovestone, Simon Nevado-Holgado, Alejo Jabstract bibtex BACKGROUND: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. METHODS: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. RESULTS: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). CONCLUSIONS: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.
@article{RN378,
author = {Newby, D. and Prieto-Alhambra, D. and Duarte-Salles, T. and Ansell, D. and Pedersen, L. and van der Lei, J. and Mosseveld, M. and Rijnbeek, P. and James, G. and Alexander, M. and Egger, P. and Podhorna, J. and Stewart, R. and Perera, G. and Avillach, P. and Grosdidier, S. and Lovestone, S. and Nevado-Holgado, A. J.},
title = {Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study},
journal = {Alzheimers Res Ther},
volume = {12},
number = {1},
pages = {38},
note = {1758-9193 Newby, Danielle Prieto-Alhambra, Daniel Duarte-Salles, Talita Ansell, David Pedersen, Lars van der Lei, Johan Mosseveld, Mees Rijnbeek, Peter James, Glen Alexander, Myriam Egger, Peter Podhorna, Jana Stewart, Robert Perera, Gayan Avillach, Paul Grosdidier, Solène Lovestone, Simon Nevado-Holgado, Alejo J},
abstract = {BACKGROUND: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. METHODS: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. RESULTS: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). CONCLUSIONS: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.},
keywords = {Aged
*Antirheumatic Agents/therapeutic use
*Arthritis, Rheumatoid/drug therapy/epidemiology
Case-Control Studies
*Dementia/drug therapy/epidemiology
Female
Humans
Male
Methotrexate/therapeutic use
Middle Aged
Netherlands
Retrospective Studies
Risk Factors
Anti-inflammatory drugs
Case-control study
DMARDs
Dementia
Emif
European Medical Information Framework
Inflammation
Methotrexate
Rheumatoid arthritis
Sulfasalazine ,
DOI = 10.1186/s13195-020-00606-5},
year = {2020},
type = {Journal Article}
}
Downloads: 0
{"_id":"Xw32rKhFuWKK6fW8s","bibbaseid":"newby-prietoalhambra-duartesalles-ansell-pedersen-vanderlei-mosseveld-rijnbeek-etal-methotrexateandrelativeriskofdementiaamongstpatientswithrheumatoidarthritisamultinationalmultidatabasecasecontrolstudy-2020","authorIDs":[],"author_short":["Newby, D.","Prieto-Alhambra, D.","Duarte-Salles, T.","Ansell, D.","Pedersen, L.","van der Lei, J.","Mosseveld, M.","Rijnbeek, P.","James, G.","Alexander, M.","Egger, P.","Podhorna, J.","Stewart, R.","Perera, G.","Avillach, P.","Grosdidier, S.","Lovestone, S.","Nevado-Holgado, A. J."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Newby"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Prieto-Alhambra"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Duarte-Salles"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Ansell"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Pedersen"],"firstnames":["L."],"suffixes":[]},{"propositions":["van","der"],"lastnames":["Lei"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Mosseveld"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Rijnbeek"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["James"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Alexander"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Egger"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Podhorna"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Stewart"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Perera"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Avillach"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Grosdidier"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Lovestone"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Nevado-Holgado"],"firstnames":["A.","J."],"suffixes":[]}],"title":"Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study","journal":"Alzheimers Res Ther","volume":"12","number":"1","pages":"38","note":"1758-9193 Newby, Danielle Prieto-Alhambra, Daniel Duarte-Salles, Talita Ansell, David Pedersen, Lars van der Lei, Johan Mosseveld, Mees Rijnbeek, Peter James, Glen Alexander, Myriam Egger, Peter Podhorna, Jana Stewart, Robert Perera, Gayan Avillach, Paul Grosdidier, Solène Lovestone, Simon Nevado-Holgado, Alejo J","abstract":"BACKGROUND: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. METHODS: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. RESULTS: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). CONCLUSIONS: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.","keywords":"Aged *Antirheumatic Agents/therapeutic use *Arthritis, Rheumatoid/drug therapy/epidemiology Case-Control Studies *Dementia/drug therapy/epidemiology Female Humans Male Methotrexate/therapeutic use Middle Aged Netherlands Retrospective Studies Risk Factors Anti-inflammatory drugs Case-control study DMARDs Dementia Emif European Medical Information Framework Inflammation Methotrexate Rheumatoid arthritis Sulfasalazine , DOI = 10.1186/s13195-020-00606-5","year":"2020","bibtex":"@article{RN378,\r\n author = {Newby, D. and Prieto-Alhambra, D. and Duarte-Salles, T. and Ansell, D. and Pedersen, L. and van der Lei, J. and Mosseveld, M. and Rijnbeek, P. and James, G. and Alexander, M. and Egger, P. and Podhorna, J. and Stewart, R. and Perera, G. and Avillach, P. and Grosdidier, S. and Lovestone, S. and Nevado-Holgado, A. J.},\r\n title = {Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study},\r\n journal = {Alzheimers Res Ther},\r\n volume = {12},\r\n number = {1},\r\n pages = {38},\r\n note = {1758-9193 Newby, Danielle Prieto-Alhambra, Daniel Duarte-Salles, Talita Ansell, David Pedersen, Lars van der Lei, Johan Mosseveld, Mees Rijnbeek, Peter James, Glen Alexander, Myriam Egger, Peter Podhorna, Jana Stewart, Robert Perera, Gayan Avillach, Paul Grosdidier, Solène Lovestone, Simon Nevado-Holgado, Alejo J},\r\n abstract = {BACKGROUND: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. METHODS: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. RESULTS: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). CONCLUSIONS: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.},\r\n keywords = {Aged\r\n*Antirheumatic Agents/therapeutic use\r\n*Arthritis, Rheumatoid/drug therapy/epidemiology\r\nCase-Control Studies\r\n*Dementia/drug therapy/epidemiology\r\nFemale\r\nHumans\r\nMale\r\nMethotrexate/therapeutic use\r\nMiddle Aged\r\nNetherlands\r\nRetrospective Studies\r\nRisk Factors\r\nAnti-inflammatory drugs\r\nCase-control study\r\nDMARDs\r\nDementia\r\nEmif\r\nEuropean Medical Information Framework\r\nInflammation\r\nMethotrexate\r\nRheumatoid arthritis\r\nSulfasalazine ,\r\nDOI = 10.1186/s13195-020-00606-5},\r\n year = {2020},\r\n type = {Journal Article}\r\n}\r\n\r\n","author_short":["Newby, D.","Prieto-Alhambra, D.","Duarte-Salles, T.","Ansell, D.","Pedersen, L.","van der Lei, J.","Mosseveld, M.","Rijnbeek, P.","James, G.","Alexander, M.","Egger, P.","Podhorna, J.","Stewart, R.","Perera, G.","Avillach, P.","Grosdidier, S.","Lovestone, S.","Nevado-Holgado, A. J."],"key":"RN378","id":"RN378","bibbaseid":"newby-prietoalhambra-duartesalles-ansell-pedersen-vanderlei-mosseveld-rijnbeek-etal-methotrexateandrelativeriskofdementiaamongstpatientswithrheumatoidarthritisamultinationalmultidatabasecasecontrolstudy-2020","role":"author","urls":{},"keyword":["Aged *Antirheumatic Agents/therapeutic use *Arthritis","Rheumatoid/drug therapy/epidemiology Case-Control Studies *Dementia/drug therapy/epidemiology Female Humans Male Methotrexate/therapeutic use Middle Aged Netherlands Retrospective Studies Risk Factors Anti-inflammatory drugs Case-control study DMARDs Dementia Emif European Medical Information Framework Inflammation Methotrexate Rheumatoid arthritis Sulfasalazine","DOI = 10.1186/s13195-020-00606-5"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/network/files/qwipow2DJsAxqNp83","creationDate":"2021-01-29T14:37:24.285Z","downloads":0,"keywords":["aged *antirheumatic agents/therapeutic use *arthritis","rheumatoid/drug therapy/epidemiology case-control studies *dementia/drug therapy/epidemiology female humans male methotrexate/therapeutic use middle aged netherlands retrospective studies risk factors anti-inflammatory drugs case-control study dmards dementia emif european medical information framework inflammation methotrexate rheumatoid arthritis sulfasalazine","doi = 10.1186/s13195-020-00606-5"],"search_terms":["methotrexate","relative","risk","dementia","amongst","patients","rheumatoid","arthritis","multi","national","multi","database","case","control","study","newby","prieto-alhambra","duarte-salles","ansell","pedersen","van der lei","mosseveld","rijnbeek","james","alexander","egger","podhorna","stewart","perera","avillach","grosdidier","lovestone","nevado-holgado"],"title":"Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study","year":2020,"dataSources":["xnfSapys2DoEfaJa2","oJZGB5PnqjLfyucHk","PJSqX8FMpCPRdw3CQ","qLDnCcKM9omXNrRY8","TB9sD3avjy7bNxfgS","vDmJPYmHEKAT3tMNL","PcZMFHooKwpboi2he","jZMXEeHTfokmisJDv"]}